Treatment-related progressive multifocal leukoencephalopathy (PML) has been reported in multiple sclerosis (MS) patients on monotherapy with several disease-modifying treatments, that is, natalizumab, fingolimod and dimethylfumarate, emphasising the importance of pharmacovigilance and the need for an increasing understanding of risk factors.
Treatment-related progressive multifocal leukoencephalopathy (PML) has been reported in multiple sclerosis (MS) patients on monotherapy with several disease-modifying treatments, that is, natalizumab, fingolimod and dimethylfumarate, emphasising the importance of pharmacovigilance and the need for an increasing understanding of risk factors.
Applying the STRATIFY anti-JC virus (JCV) antibody test in serum, natalizumab-naive MS cohorts show JCV seropositivity in about 50-60% of patients. 1, 2 It is well documented that patients who have no anti-JCV antibodies have a negligible risk of PML. However, several studies have addressed the risk of PML after JCV seroconversion and the impact of the level of JCV indexes during prolonged treatment with natalizumab. [1] [2] [3] [4] [5] [6] [7] Weak but significant associations of JCV antibody seroconversion with patient demographics have been reported, suggesting a higher prevalence with increasing age, in male patients and some countries of residence. 6, 7 However, the majority of studies so far have included cross-sectional data only, or had short follow-up times of longitudinal samples and treatment duration, limiting their conclusions. In those studies reporting larger groups of older patients on natalizumab (above 60 years of age), about 35% of patients still seem to be JCV negative. Unfortunately, reliable data on JCV antibody seroconversion in the general population are scarce. [6] [7] [8] In this issue of Multiple Sclerosis Journal, Raffel and colleagues report an annualised seroconversion rate in initially seronegative patients of 15.4% using the second generation STRATIFY test only. 9 Distinct from others reporting high seroconversion rates without the availability of longer term follow-up data, they show persistently high conversion rates in those who have been on treatment longer, that is, 16% in patients 4-7 years after the initiation of natalizumab.
Moreover, the authors suggest that the use of natalizumab is associated with an increase in the JCV antibody index over time, independently of increasing age. Even though the increase in the anti-JCV antibody index of 0.136 per year seems rather modest, this finding may be clinically relevant during longterm treatment. Especially when taking into account the fact that the increase in years 2-4 is more than double the increase in years 0-2 in the London study. Interestingly, the authors show that the increase would not have been detected based on cross-sectional analyses alone, that is, correlating all available anti-JCV antibody titres with duration of treatment, emphasising the additive value of a longitudinal approach. 9 High JCV antibody seroconversion rates in natalizumab-treated MS patients have been demonstrated by others. Plavina and colleagues reported 13% seroconversion during 18 months of follow-up in initially negative patients. 2 Warnke et al. reported 10.3% with a median follow-up of 12 months. 5 Other studies had even more limited follow-up or were restricted by comparing the results of different versions of the assays. 3 The European Medicines Agency (EMA) recently decided to start an investigation based on the reported seroconversion rate of 13% (18 months follow-up) in natalizumab-treated MS patients to reassess whether current recommendations of testing every 6 months should be reconsidered. 10 The data presented by Raffel and colleagues emphasise the need for greater clarification. 9 What can we conclude based on the data presented in this study? In addition to the exceptionally high annualised seroconversion rate, the data clearly suggest that JCV antibody indexes increase during long-term treatment. Importantly, the observed increase in JCV indexes during natalizumab exposure would have been missed without timely serial measurements and analyses. Obviously, the persistently high conversion rate during longer follow-up and the more than doubled increase in indexes in patients with longer exposure has clinical relevance.
How can these findings be explained? The authors deliberated on the increase in peripheral sequestration
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of leucocytes leading to increased peripheral immune activity and higher antibody production and the mobilisation of peripheral blood mononuclear cells harbouring latent infection. Another possible explanation for the higher than expected seroconversion rate in natalizumab users might be the reported decrease of lymphocytes in the intestinal mucosa in natalizumabtreated patients, probably resulting in less immunity in the gastrointestinal tract and as a consequence a higher risk of primary infection.
What further data are needed? First, more long-term longitudinal data in initially JCV-negative and low index-positive patients should be collected and presented. The further increase in indexes during longer follow-up may be very relevant, although the increased risk of PML in seroconverters and those patients who rise from low to high indexes has not yet been fully established. Second, future research should focus on reliable predictors of PML and enhanced pharmacovigilance programmes in high index JCVpositive patients in order to prevent or detect PML at a very early stage. Do high seroconversion rates and increasing JCV indexes have clinical implications yet? We believe that -even though definite conclusions cannot be drawnthe high conversion rates, including JCV index escalation, should be discussed with seronegative and low index patients before treatment initiation. This should also imply the frequently encountered difficulties around switching, including rebound disease activity. 11 We agree with Raffel and colleagues that natalizumab is very effective and -apart from the risk of PML -is very well tolerated. Even though the majority of patients with high indexes and continued natalizumab usage do not develop PML during currently available follow-up, the extent of the role of natalizumab in future clinical practice will largely depend on definitive figures on long-term JCV antibody seroconversion, the availability of reliable predictors in patients at risk of PML and the safety and efficacy of other emerging treatments for MS.
